BIOLINERX
Facebook
|
Twitter
|
Linkedin
| Careers | Contact Us
search

2013 Press releases
E-mail Alerts Receive e-mail alerts | RSS Rss feeds
Keyword search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
12/18/13BioLineRx Enters Clinic with Novel Treatment for Celiac DiseasePrinter Friendly Version
12/16/13BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia TreatmentPrinter Friendly Version
12/10/13BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH ConferencePrinter Friendly Version
11/26/13BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease TreatmentPrinter Friendly Version
11/19/13BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple MyelomaPrinter Friendly Version
11/13/13BioLineRx Reports Third Quarter 2013 Financial ResultsPrinter Friendly Version
11/06/13BioLineRx to Report Third Quarter 2013 Results on November 13, 2013Printer Friendly Version
11/05/13BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013Printer Friendly Version
11/04/13BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac DiseasePrinter Friendly Version
10/23/13BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 DiabetesPrinter Friendly Version
10/07/13BioLineRx Announces Receipt of Notice of Allowance from USPTO for Patent Covering BL-5010, a Novel Treatment for Removal of Skin LesionsPrinter Friendly Version
09/24/13BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac DiseasePrinter Friendly Version
09/17/13BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis CPrinter Friendly Version
09/09/13BioLineRx's BL-8040 Receives Orphan Drug Designation for Treatment of AMLPrinter Friendly Version
09/03/13BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New YorkPrinter Friendly Version
09/03/13BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem CellsPrinter Friendly Version
08/28/13BioLineRx to Present at 15th International Celiac Disease SymposiumPrinter Friendly Version
08/27/13BioLineRx to Present at 2013 Stifel Nicolaus Healthcare Conference In BostonPrinter Friendly Version
08/19/13BioLineRx Appoints B. J. Bormann to Board of DirectorsPrinter Friendly Version
08/06/13BioLineRx Reports Second Quarter 2013 ResultsPrinter Friendly Version
08/05/13BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040 in Treatment of Thrombocytopenia Printer Friendly Version
07/30/13BioLineRx to Report Second Quarter 2013 Results on August 6, 2013Printer Friendly Version
07/29/13BioLineRx Announces CE-Mark Registration Trial Submission for Novel Treatment for Removal of Skin LesionsPrinter Friendly Version
07/02/13BioLineRx to Present at 2013 Annual JMP Securities Healthcare Conference in New YorkPrinter Friendly Version
06/10/13BioLineRx Enters into Collaboration to Develop and Commercialize Hepatitis C Drug with CTTQ, Leading Chinese Pharma Company for Liver Disease TherapeuticsPrinter Friendly Version
06/06/13BioLineRx Enrolls First Patient in Phase 2 Clinical Trial for BL-8040, for Treatment of LeukemiaPrinter Friendly Version
05/17/13BioLineRx Enters into “At-The-Market” Offering Agreement with Stifel, Nicolaus & CompanyPrinter Friendly Version
05/09/13BioLineRx to Present at the Oppenheimer 14th Annual Israeli Conference on May 12thPrinter Friendly Version
05/07/13BioLineRx Reports First Quarter 2013 ResultsPrinter Friendly Version
05/02/13BioLineRx's BL-7010, for the Treatment of Celiac, to be Presented at Two Leading ConferencesPrinter Friendly Version
04/30/13BioLineRx to Report First Quarter 2013 Results on May 7, 2013Printer Friendly Version
04/29/13BioLineRx Enrolls First Patient in Phase I/II Clinical Trial for BL-8020, an Oral, Interferon-Free Treatment for Hepatitis CPrinter Friendly Version
04/18/13BioLineRx to Present at the 12th Annual Needham Healthcare Conference in New York on April 30, 2013Printer Friendly Version
04/17/13BioLineRx Announces Positive Phase II Results for BL-7040, an Orally Available Treatment for Inflammatory Bowel DiseasePrinter Friendly Version
04/10/13BioLineRx Receives Regulatory Approval to Commence Phase II Clinical Trial for BL-8040, for Treatment of LeukemiaPrinter Friendly Version
03/20/13BioLineRx Announces Results from Interim Analysis of Phase II/III CLARITY Trial of BL-1020 for SchizophreniaPrinter Friendly Version
03/13/13BioLineRx Receives Approval from French Regulatory Authorities to Commence a Phase I/II Clinical Trial for BL-8020, an Oral, Interferon-Free Treatment for Hepatitis CPrinter Friendly Version
03/12/13BioLineRx Reports Year End 2012 Financial ResultsPrinter Friendly Version
02/28/13BioLineRx's EDP-14, for Treatment of Severe and Persistent Asthma, to Enter the Company's Main Therapeutic Pipeline as BL-9010Printer Friendly Version
02/26/13BioLineRx to Report Fourth Quarter and Year End 2012 Results on March 12, 2013Printer Friendly Version
02/13/13BioLineRx Announces Closing of $8 Million Offering of American Depositary SharesPrinter Friendly Version
02/06/13BioLineRx Announces Offering of American Depositary SharesPrinter Friendly Version
02/04/13BioLineRx Provides Clarification Regarding Interim Analysis of CLARITY Trial for BL-1020Printer Friendly Version
01/31/13BioLineRx to Present at the 2013 BIO CEO & Investor Conference in New York on February 12thPrinter Friendly Version
01/07/13BioLineRx to Announce Interim Results of Phase II/III Trial for Schizophrenia Drug During Week of March 18, 2013Printer Friendly Version


Interview with Philip Serlin, CEO
December 2016